作者@article {Sculier915 = {j]。Sculier和d . Moro-Sibilot},标题={一线和二线治疗先进nonsmall细胞肺癌},体积={33}={4},页面= {915 - 930}= {2009},doi ={10.1183/09031936.00132008},出版商={欧洲呼吸学会},文摘={目标治疗先进nonsmall细胞肺癌的姑息,改善生存,症状控制、生活质量和成本。188bet官网地址这些好处的证据级别是基于多个随机试验和荟萃分析。Cisplatin-based化疗的方法证明是有效的应该是首选。卡铂可能代替顺铂如果医疗禁忌症存在。Nonplatinum-based方案表示作为一线治疗先进nonsmall细胞肺癌的病人来说,以铂为基础的化疗是禁忌。单药化疗患者可能被认为表现不佳状态。活性药物的选择取决于病人{\ textquoteright}年代医疗条件。没有确凿的证据表明,高剂量顺铂(100 120毫克{\ textendash} {\ textperiodcentered} m - 2)提供更好的结果比标准低剂量(50 60毫克{\ textendash} {\ textperiodcentered} m - 2)的生存。化疗的最佳时间是不记录在先进nonsmall细胞肺癌。 A minimum of four to six cycles is advised in responding patients. Second-line chemotherapy is now accepted as a standard and should be offered to patients with good performance status and failing platinum-based first-line chemotherapy. Evidence is in favour of docetaxel and in the case of adenocarcinoma and adequate renal function, pemetrexed is recommended. SERIES {\textquotedblleft}LUNG CANCER{\textquotedblright} Edited by C. Brambilla Number 4 in this Series}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/33/4/915}, eprint = {//www.qdcxjkg.com/content/33/4/915.full.pdf}, journal = {European Respiratory Journal} }